Key Points
- CEO Martine Rothblatt sold 9,500 United Therapeutics shares at an average price of $494.55, generating approximately $4.70 million. She retains 324,443 shares valued at about $160.45 million.
- United Therapeutics reported quarterly EPS of $7.27, beating estimates of $6.86, while revenue of $783.3 million fell short of expectations and declined 1.9% year over year.
- Analysts maintain a favorable outlook, with a consensus rating of “Moderate Buy” and an average price target of $646, despite the stock trading below its 50-day and 200-day moving averages.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the firm's stock in a transaction that occurred on Monday, September 21st. The shares were sold at an average price of $494.55, for a total value of $4,698,225.00. Following the completion of the sale, the chief executive officer directly owned 324,443 shares of the company's stock, valued at $160,453,285.65. The trade was a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
United Therapeutics Stock Performance
NASDAQ:UTHR opened at $497.59 on Wednesday. The stock's fifty day moving average is $514.05 and its 200 day moving average is $540.51. United Therapeutics Corporation has a fifty-two week low of $409.07 and a fifty-two week high of $609.35. The firm has a market capitalization of $21.34 billion, a PE ratio of 17.80, a PEG ratio of 2.47 and a beta of 0.56.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping the consensus estimate of $6.86 by $0.41. The company had revenue of $783.30 million during the quarter, compared to analyst estimates of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. United Therapeutics's quarterly revenue was down 1.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $6.41 earnings per share. Equities analysts forecast that United Therapeutics Corporation will post 26.21 EPS for the current year.
Institutional Investors Weigh In On United Therapeutics
Hedge funds have recently made changes to their positions in the company. Arjuna Capital raised its holdings in shares of United Therapeutics by 2.8% in the 1st quarter. Arjuna Capital now owns 662 shares of the biotechnology company's stock valued at $393,000 after purchasing an additional 18 shares in the last quarter. Sage Rhino Capital LLC raised its stake in United Therapeutics by 5.1% in the first quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company's stock worth $281,000 after buying an additional 23 shares in the last quarter. Bryn Mawr Trust Advisors LLC lifted its holdings in United Therapeutics by 5.4% during the first quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company's stock worth $276,000 after buying an additional 24 shares during the period. Meeder Advisory Services Inc. boosted its position in United Therapeutics by 4.1% during the 1st quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company's stock valued at $392,000 after acquiring an additional 26 shares in the last quarter. Finally, Kera Capital Partners Inc. boosted its position in United Therapeutics by 6.1% during the 1st quarter. Kera Capital Partners Inc. now owns 471 shares of the biotechnology company's stock valued at $279,000 after acquiring an additional 27 shares in the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of research firms have recently commented on UTHR. Weiss Ratings cut United Therapeutics from a "buy (b)" rating to a "buy (b-)" rating in a research note on Thursday, August 27th. Bank of America lowered their target price on shares of United Therapeutics from $620.00 to $613.00 and set a "neutral" rating for the company in a research note on Friday, July 10th. JPMorgan Chase & Co. upped their price target on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an "overweight" rating in a report on Thursday, July 23rd. Morgan Stanley set a $515.00 price target on shares of United Therapeutics in a research note on Thursday, August 6th. Finally, Royal Bank Of Canada decreased their price objective on shares of United Therapeutics from $704.00 to $677.00 and set an "outperform" rating for the company in a report on Thursday, August 6th. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat, United Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $646.00.
View Our Latest Report on United Therapeutics
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company's products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.
United Therapeutics' PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
